Vitex/Chasteberry: The Complete Supplement Guide

Quick Reference Card

Overview

The Basics

Vitex agnus-castus, commonly known as chasteberry or chaste tree berry, is one of the oldest known herbal remedies for women's health. The berry comes from a small tree native to the Mediterranean and Central Asia, and it has been used for gynecological complaints for over 2,500 years. The ancient Greeks wrote about it, medieval monks reportedly consumed it to suppress sexual desire (which is where the name "chasteberry" comes from), and it remains one of the most widely prescribed herbal medicines for premenstrual syndrome in Europe today [1][2].

The primary modern use of chasteberry is managing symptoms of premenstrual syndrome (PMS) and premenstrual dysphoric disorder (PMDD). Multiple clinical trials have shown that it can reduce breast tenderness, mood changes, bloating, headaches, and irritability that many women experience in the days before their period [3][4]. It is also sometimes used for menstrual irregularities, breast pain (mastalgia), and fertility issues related to a condition called luteal phase deficiency [5].

What makes chasteberry interesting from a pharmacological standpoint is that it does not contain hormones itself. Instead, it appears to work by influencing the brain's regulation of hormone release, particularly by acting on dopamine receptors in the pituitary gland. This action reduces prolactin levels, which in turn can normalize the balance between estrogen and progesterone during the menstrual cycle [6]. The result is not adding hormones to the body but rather helping the body regulate its own hormone production more effectively.

The Science

Vitex agnus-castus L. (formerly Verbenaceae, now classified under Lamiaceae) is a deciduous shrub or small tree cultivated throughout the Mediterranean basin, Central Asia, and parts of southern Europe. The pharmacologically active parts are the ripe dried fruits (berries), which contain a complex phytochemical profile including labdane-type diterpenoids (rotundifuran, vitexilactone, vitexlactam A), clerodane diterpenoids (clerodadienols), flavonoids (casticin, penduletin, apigenin, luteolin, 3-methylkaempferol), iridoid glycosides (agnuside, aucubin), essential oils, and fatty acids including linoleic acid [1][7].

The berry composition includes rotundifuran at 1.04-2.23% dry weight, vitexilactone at 0.33-1% dry weight, and casticin at 0.5-1.2% dry weight, with leaves containing substantially higher polyphenolic content (3.15% dry weight as caffeic acid equivalents) than roots [7]. Historical use spans Greco-Roman, Ayurvedic, and traditional European herbal medicine systems, where chasteberry was employed for amenorrhea, menstrual irregularities, mastodynia, and as an anaphrodisiac [1][2].

The European Medicines Agency (EMA) has issued a well-established use monograph for Vitex agnus-castus dry extract for the relief of premenstrual complaints, recognizing a sufficient body of clinical evidence [8]. In Germany, chasteberry preparations have been among the most frequently prescribed herbal medicines for gynecological conditions for several decades [2].

Chemical & Nutritional Identity

Common supplement forms and their characteristics:

• Whole dried berry powder: The simplest form, containing the full phytochemical spectrum. Typical doses range from 150-250 mg/day. Less standardized than concentrated extracts.
• BNO 1095 (Agnucaston): A 70:30 ethanolic:water extract with a 10:1 concentration ratio. This means 4 mg of BNO 1095 is equivalent to approximately 40 mg of dried fruit. This is the most extensively studied extract in clinical trials for PMS [3][9].
• Ze 110: A 60% ethanolic extract with a 6-12:1 drug-to-extract ratio, standardized for casticin content. Typically dosed at 20 mg/day. Also well-studied for PMS [4][10].
• Ze 440: Another standardized extract used in the landmark Schellenberg (2001) trial at 20 mg/day [3].
• Liquid tinctures: Hydroalcoholic extracts, often dosed at 40 drops daily (approximately 4.5 mg of extract). Used in several clinical trials [4].
• Essential oil (topical): Prepared from leaves and fruits, studied as a 1.5% cream for menopausal symptoms in one trial [11].

Mechanism of Action

The Basics

Chasteberry works through a somewhat unusual mechanism for an herbal supplement. Rather than directly introducing hormones into the body or acting on a single target, it influences several interconnected systems in the brain that regulate hormone release. Think of it as adjusting the thermostat rather than manually heating or cooling the room.

The most important mechanism involves dopamine, one of the brain's key signaling chemicals. Certain compounds in chasteberry (particularly the clerodadienol diterpenes) can activate dopamine receptors in the pituitary gland, the small hormonal control center at the base of the brain [6][12]. When these receptors are activated, the pituitary releases less prolactin. This matters because elevated prolactin levels are linked to breast tenderness, disrupted menstrual cycles, and insufficient production of progesterone in the second half of the cycle (the luteal phase) [5][13].

Chasteberry also interacts with the body's internal opioid system. A flavonoid called casticin activates delta-opioid receptors, which may help release beta-endorphins (the body's natural painkillers and mood regulators). Lower beta-endorphin levels have been observed in women during menopause and the premenstrual phase, so this activity could partially explain the mood and hot flash benefits some women report [14][15].

There is also an interesting relationship with estrogen. Chasteberry contains compounds that bind to estrogen receptor beta (ERbeta) but not estrogen receptor alpha (ERalpha). Since ERalpha is the receptor typically responsible for the classic "estrogenic effects" in breast and uterine tissue, chasteberry may actually have a net anti-estrogenic effect in the body, despite being classified as containing phytoestrogens [16][17].

The Science

The pharmacological activity of Vitex agnus-castus is attributable to multiple classes of bioactive constituents operating through distinct molecular pathways:

Dopaminergic pathway (primary mechanism): Clerodane diterpenoids, particularly clerodadienols, bind to and activate dopamine D2 receptors (D2R) in anterior pituitary lactotroph cells, dose-dependently inhibiting prolactin (PRL) secretion [6][12]. In vitro, the clerodadienol fraction accounts for over 50% of the total dopaminergic activity of Vitex extracts, with the hexane and ethanolic fractions concentrating this activity while water-soluble fractions show negligible dopaminergic effects [7]. Rotundifuran (IC50 45 +/- 7 ug/mL) and linoleic acid (IC50 40 +/- 12 ug/mL) also contribute to D2R binding [7]. The PRL-suppressive effect has been confirmed in vivo, with casticin injections at 10, 20, and 40 mg/kg reducing prolactin by 33.9%, 54.3%, and 64.7% respectively in rats, with 15 mg/kg casticin approximating the efficacy of 1 mg/kg bromocriptine [7][13].

Opioidergic pathway: Casticin (3',5-dihydroxy-3,4',6,7-tetramethoxyflavone) exerts agonistic activity at mu- and delta-opioid receptor subtypes, with IC50 values of 2.84 +/- 0.707 uM and 2.05 +/- 0.631 uM respectively [14][15]. Delta-opioid receptor activation (EC50 15.3 +/- 6.32 uM, Emax 74.6 +/- 18.2%) may stimulate beta-endorphin release, which is inversely correlated with vasomotor and mood symptoms of PMS and menopause [14].

Estrogenic/anti-estrogenic pathway: Vitex extracts demonstrate selective affinity for estrogen receptor beta (ERbeta) with an EC50 of approximately 10 ug/mL for the BN1095 extract, mediated primarily by penduletin (EC50 0.25 ug/mL) and apigenin [16][17]. Critically, no significant binding to ERalpha has been consistently demonstrated across studies, and no induction of estrogen-dependent alkaline phosphatase (an ERalpha-mediated effect) has been observed [16]. This ERbeta selectivity suggests a functionally anti-estrogenic profile, as ERbeta activation can antagonize ERalpha-mediated proliferative effects in breast and uterine tissue [17]. Apigenin additionally demonstrates progestogenic activity [17].

Hypothalamic-pituitary-gonadal axis effects: In human studies, chasteberry restores luteal-phase progesterone concentrations, prolongs the hyperthermic phase of the basal body temperature curve, and normalizes the LHRH stimulation test, suggesting action at the pituitary-hypothalamic level rather than direct ovarian effects [5][17].

CYP enzyme inhibition: In vitro, Vitex ethanolic extract inhibits CYP1A2 (IC50 3.8 ug/mL), CYP2C19 (IC50 0.22 ug/mL), CYP2D6 (IC50 2.9 ug/mL), and CYP3A4 (IC50 0.3 ug/mL), raising theoretical concerns about drug-herb interactions, though clinical relevance remains undetermined [18].

Absorption & Bioavailability

The Basics

Detailed pharmacokinetic data for chasteberry in humans is limited compared to many other supplements. What is known is that the form and extraction method significantly influence how much of the active compounds your body can actually use.

Standardized ethanolic extracts (like BNO 1095 and Ze 110) are designed to concentrate the most pharmacologically active compounds, particularly the diterpenes and flavonoids that are responsible for the dopaminergic and opioidergic effects. These compounds are fat-soluble, which means they are better extracted by alcohol-based solvents than by water alone. This is why water-based preparations (teas, water extracts) show negligible dopaminergic activity in laboratory testing, while ethanolic extracts retain the full range of activity [7].

The concentration ratios matter practically. A 10:1 extract like BNO 1095 means that 4 mg of the extract contains the active compounds from approximately 40 mg of dried berry. A 6-12:1 extract like Ze 110 at 20 mg delivers the equivalent of roughly 120-240 mg of dried berry. This is why dosing varies so dramatically between forms: 4 mg of a concentrated extract can deliver similar benefits to 150-250 mg of a less concentrated powder [7][9].

The Science

Pharmacokinetic data for individual Vitex agnus-castus constituents in humans are sparse. The following observations derive from in vitro and preclinical data:

The bioactive compounds of primary pharmacological interest, particularly the clerodane diterpenoids and casticin, are lipophilic. In vitro studies demonstrate that dopaminergic activity is concentrated exclusively in hexane and ethanolic fractions, with water, butanol, and chloroform fractions showing no significant D2R binding activity [7]. This lipophilicity profile explains the superiority of ethanol-based extraction methods (60-70% ethanol) over aqueous preparations for therapeutic applications.

The drug-to-extract ratio influences clinical efficacy through differential concentration of active constituents. BNO 1095 (10:1, 70:30 ethanol:water) and Ze 110 (6-12:1, 60% ethanol) represent the two most clinically validated extraction profiles, with standardization for casticin (Ze 110: 0.5-1.2% dry weight) or total diterpenoid content providing quality control benchmarks [7][9].

In men, an open-label trial showed dose-dependent effects on melatonin secretion, with 120 mg and 480 mg of a 5:1 extract increasing melatonin AUC by approximately 20%, with greater significance during sleep hours [19]. This suggests systemic bioavailability of neuroactive constituents following oral administration.

Research & Clinical Evidence

PMS and PMDD

The Basics

Premenstrual syndrome is the condition for which chasteberry has the strongest evidence. Several clinical trials, including blinded studies where neither the participants nor the researchers knew who was getting the real supplement, have found that chasteberry reduces overall PMS symptoms significantly better than a placebo [3][4][10].

In the most well-known trial (Schellenberg, 2001), 178 women took either 20 mg of a standardized chasteberry extract or a placebo for three menstrual cycles. The women taking chasteberry reported significantly greater improvement in symptoms including irritability, mood changes, headaches, and breast tenderness. Over half of the chasteberry group experienced at least a 50% reduction in symptoms, compared to about a quarter in the placebo group [3].

A 2019 meta-analysis that applied strict quality standards found only three of 21 available clinical trials met rigorous criteria, but those three studies (totaling 520 women) confirmed that women taking chasteberry were 2.57 times more likely to experience symptom remission than those taking a placebo [20]. An earlier, broader meta-analysis (2017) found a large pooled effect size but cautioned that high heterogeneity and risk of bias across studies meant the true effect might be somewhat smaller than the pooled estimate suggests [4].

Some evidence also suggests that chasteberry may be comparable in effectiveness to the SSRI antidepressant fluoxetine for PMS symptoms, and similar to vitamin B6, though these comparisons come from individual trials rather than head-to-head meta-analyses [21][4].

The Science

The clinical evidence base for Vitex agnus-castus in PMS/PMDD comprises multiple randomized controlled trials and three systematic reviews/meta-analyses:

Csupor et al. (2019) meta-analysis [20]: Applied strict CONSORT-aligned criteria to 21 identified trials. Only 3 double-blind RCTs with properly characterized VAC preparations met inclusion criteria (total n=520). Summary relative risk for symptom remission: RR 2.57 (95% CI 1.52-4.35, p<0.001) favoring VAC over placebo. The authors note that incomplete product characterization in most published trials limits the usable evidence base.

Verkaik et al. (2017) meta-analysis [4]: Broader inclusion criteria yielded 17 RCTs, 14 included in quantitative analysis. Pooled effect size: Hedges' g = -1.21 (95% CI -1.53 to -0.88), indicating a large treatment effect. However, heterogeneity was extremely high (I-squared not reported but described as "extreme"), and both risk of bias and risk of publication bias were elevated. The authors characterize the pooled effect as "exploratory" and "likely overestimating the real treatment effect."

Van Die et al. (2013) systematic review [22]: Identified 12 qualifying RCTs across PMS (8 trials), PMDD (2 trials), and latent hyperprolactinemia (2 trials). For PMS, 7 of 8 trials reported VAC superior to comparators (placebo in 5/6, pyridoxine in 1, magnesium oxide in 1). For PMDD, results were mixed: one trial found VAC equivalent to fluoxetine [21], while another found fluoxetine outperformed VAC. Methodological quality was generally moderate-to-high.

Schellenberg (2001) landmark RCT [3]: Double-blind, placebo-controlled, n=178 women with PMS. Ze 440 extract 20 mg/day for 3 cycles. Primary outcome: self-assessment improvement 52% vs. 24% (p<0.001). Secondary outcomes showed significant improvements in irritability, mood alteration, anger, headache, and breast fullness.

He et al. (2009) Chinese RCT [9]: Placebo-controlled, n=217. BNO 1095 4 mg/day for 3 cycles in Chinese women with moderate-to-severe PMS. Overall symptom reduction: 63% vs. 46% for placebo. Effective for emotional and physical symptoms but did not significantly improve lower abdominal cramping.

Mastalgia (Cyclical Breast Pain)

The Basics

Cyclical breast pain, the tenderness and swelling that many women experience before their period, is one of the symptoms most consistently improved by chasteberry in clinical trials. This makes mechanistic sense: breast tenderness is closely linked to elevated prolactin levels, and chasteberry's primary action is reducing prolactin through dopamine receptor activation [5][13].

A systematic review and meta-analysis of chasteberry for cyclical mastalgia (2020) found evidence supporting its use, though the authors noted that more high-quality studies are needed [23]. Individual trials have reported dramatic reductions in breast pain scores, with some showing improvement comparable to bromocriptine, a prescription dopamine agonist [22].

The Science

Ooi et al. (2020) conducted a systematic review and meta-analysis specifically examining VAC for cyclical mastalgia, finding supportive but heterogeneous evidence for efficacy [23]. The mechanistic rationale is well-established: latent hyperprolactinemia during the luteal phase stimulates proliferation of mammary gland tissue and increases sensitivity to estradiol, producing the characteristic tenderness [5][13]. VAC's D2R-mediated prolactin suppression directly addresses this pathophysiology.

In the Van Die (2013) systematic review, one trial found VAC comparable to bromocriptine for reducing serum prolactin levels and ameliorating cyclic mastalgia, while another demonstrated superiority over placebo for reducing TRH-stimulated prolactin secretion [22].

Luteal Phase Deficiency and Fertility

The Basics

Luteal phase deficiency is a condition where the second half of the menstrual cycle (after ovulation) is too short, or where progesterone levels during this phase are too low for successful implantation of a fertilized egg. This is a recognized cause of infertility and recurrent pregnancy loss [5].

One well-designed trial (Milewicz et al., 1993) found that 20 mg of chasteberry daily for three months normalized shortened luteal phases, reduced excessive prolactin release, and restored progesterone production in women with luteal phase defects caused by mild prolactin elevation. Two women in the treatment group became pregnant during the study [5]. The mechanism is thought to work through prolactin reduction: when prolactin is too high, it can directly inhibit luteal progesterone secretion, shortening the luteal phase and undermining fertility [13].

However, the evidence base for fertility is limited to this single trial and case reports. Women considering chasteberry for fertility should be aware that it should be discontinued if pregnancy occurs, as safety during pregnancy has not been established [24].

The Science

Milewicz et al. (1993) [5]: Randomized double-blind placebo-controlled trial, n=52 women with luteal phase defects due to latent hyperprolactinemia. VAC preparation (Strotan capsules) 20 mg/day for 3 months. Results: TRH-stimulated prolactin release significantly reduced, shortened luteal phases normalized, luteal progesterone synthesis deficits eliminated (all changes significant only in verum group). 17-beta-estradiol increased in the luteal phase in the treatment group. No side effects observed; 2 pregnancies in the treatment group.

The pathophysiological model proposed by Wuttke et al. (2003) [13] posits that exaggerated prolactin pulses during the luteal phase directly inhibit corpus luteum progesterone secretion, creating a self-reinforcing cycle of luteal insufficiency. VAC's dopaminergic activity interrupts this cycle by reducing pituitary prolactin output, thereby restoring adequate progesterone synthesis and normalizing the luteal phase length.

Menopause

The Basics

Despite theoretical reasons to expect benefit (opioid receptor activation, prolactin modulation), the clinical evidence for chasteberry in menopausal symptom relief is weak. One small unblinded study using topical essential oil cream showed modest improvements in mood and hot flashes in about a third of participants, but had no placebo comparison [11]. A double-blind trial combining chasteberry with St. John's Wort found no benefit for menopausal symptoms [25]. Current evidence does not support using chasteberry specifically for menopause management [7][22].

The Science

Clinical trial evidence for VAC in menopause is limited and largely negative. Van Die et al. (2009) conducted a randomized controlled trial of Hypericum perforatum combined with Vitex agnus-castus in menopausal women with PMS-like symptoms [25]. While some improvements were noted over 16 weeks compared to placebo, the study design (combination intervention) precludes attributing effects to VAC specifically. An unblinded study using topical VAC essential oil cream (2.5 mL of 1.5% cream daily for 3 months) reported that 33% of participants experienced significant symptom reduction (primarily mood and hot flushes), 36% reported mild reduction, and 23.5% reported worsened symptoms [11]. The absence of a placebo arm severely limits interpretation given the high placebo response rate in menopausal symptom trials.

Evidence & Effectiveness Matrix

Benefits & Potential Effects

The Basics

The primary benefit of chasteberry is its ability to reduce the cluster of symptoms that make up premenstrual syndrome. For women who experience the classic PMS pattern of breast tenderness, mood changes, bloating, headaches, and irritability in the week or two before their period, chasteberry has some of the most consistent evidence of any herbal supplement [3][4][20].

The most reliably improved symptom across studies is breast tenderness (mastalgia). This makes sense given the mechanism: breast pain before periods is closely tied to prolactin surges, and chasteberry's main action is reducing prolactin [5][13][23]. Many women report that breast pain was the first symptom to improve, often within the first cycle.

Mood-related improvements are also well-documented. Clinical trials report reductions in irritability, depression, nervousness, and restlessness, with one study showing a 67.5% improvement in depression over placebo and a 55% improvement in nervousness [4]. Some evidence suggests that chasteberry may be roughly comparable to the SSRI fluoxetine for PMS-related mood symptoms, though this comparison requires further confirmation [21].

For women with menstrual irregularities, particularly those with short luteal phases or mild prolactin elevation, chasteberry may help normalize cycle length and progesterone production [5]. A small but notable body of evidence suggests it could support fertility in this specific subgroup.

The benefits appear to build gradually. Most clinical trials run for three menstrual cycles (approximately three months), and some practitioners suggest this is the minimum time needed to assess whether chasteberry is working for an individual [3][10].

The Science

The evidence-supported benefits of Vitex agnus-castus, ranked by strength of evidence:

1. PMS symptom reduction (strong evidence): Meta-analysis confirms RR 2.57 (95% CI 1.52-4.35) for symptom remission vs. placebo across double-blind RCTs [20]. Individual symptom improvements in blinded trials include breast swelling/pain (97.8% improvement over placebo), bloating (103%), depression (67.5%), restlessness (60%), nervousness (55%), and headache (31%) [4].
2. Cyclical mastalgia reduction (moderate-strong evidence): Systematic review supports efficacy, with mechanism directly linked to D2R-mediated prolactin suppression [23]. Comparable to bromocriptine in one trial [22].
3. Luteal phase normalization (moderate evidence): Single high-quality RCT demonstrates restoration of luteal phase length, progesterone synthesis, and TRH-stimulated prolactin response [5]. Mechanistically coherent with dopaminergic prolactin suppression.
4. Menstrual cycle regulation (limited evidence): Retrospective cohort data (Holler et al., 2024) and early clinical reports suggest benefits for oligomenorrhea, polymenorrhea, and secondary amenorrhea [26]. Prospective trial data is limited.
5. PMDD symptom reduction (limited evidence): Two RCTs with mixed results. One found VAC equivalent to fluoxetine [21]; another found fluoxetine superior. Insufficient evidence for definitive conclusions.

Reading about potential benefits gives you a framework. Seeing whether those benefits are showing up in your own body turns knowledge into confidence. Doserly lets you track the specific health markers relevant to this supplement, building a personal dataset that captures what's actually changing week over week.

The app's AI analytics go further than simple logging. By correlating your supplement intake with the biomarkers and health outcomes you're tracking, Doserly surfaces patterns you might miss on your own, like whether a dose adjustment three weeks ago corresponds to the improvement you're noticing now. When it's time to evaluate whether a supplement is earning its place in your stack, you have your own data to guide the decision.

Side Effects & Safety

The Basics

Chasteberry has a generally favorable safety profile based on the available clinical trial data. In most studies lasting up to three months, side effects were mild and occurred at rates similar to placebo [3][4][22]. The most commonly reported side effects include mild nausea, headaches, gastrointestinal discomfort, skin reactions (itching, rash), and occasional changes in menstrual flow [24][27].

However, there are important populations for whom chasteberry may not be appropriate. Because it has phytoestrogenic properties (even though its net effect may be anti-estrogenic), women with hormone-sensitive cancers of the breast, uterus, or ovaries should consult their oncologist before use [17][24]. The safety of chasteberry during pregnancy and breastfeeding has not been established, and most sources recommend avoiding it during these periods [24][27].

One concern that deserves attention is the potential for chasteberry to worsen symptoms in women with polycystic ovary syndrome (PCOS). Because chasteberry can increase luteinizing hormone (LH) levels, and many women with PCOS already have elevated LH, this supplement could theoretically amplify the hormonal imbalance that drives PCOS symptoms [7]. Community reports support this concern, with some PCOS users reporting increased bloating, weight gain, acne, and hair loss [community data].

Skin reactions, including pruritic exanthema (itchy rash), erythema, and worsening of preexisting acne, have been reported in case studies [7][27]. At least one study participant developed dermatitis after a single dose, suggesting possible allergic sensitivity in some individuals.

The LD50 in female rats for the ethanolic extract is 12.5 g/kg, indicating a wide safety margin. The European Medicines Agency assessment report references potential liver concerns with prolonged use (26 weeks or more), though this claim is not well-documented in the accessible literature [7][8].

The Science

Safety data from systematic reviews indicate that adverse events associated with VAC are generally mild and infrequent, with incidence comparable to placebo in controlled trials [4][22][27].

Reported adverse reactions include:

• Gastrointestinal: Nausea, stomach pain, diarrhea (most common)
• Neurological: Headache (mild, typically resolves)
• Dermatological: Pruritus, erythematous rash, acne exacerbation, pruritic exanthema [7][27]
• Menstrual: Intermenstrual bleeding, prolonged menstrual periods (infrequent) [7]

Contraindications:

• Pregnancy and lactation: Insufficient safety data; theoretical risk of hormonal disruption [24][27]
• Hormone-sensitive cancers: Phytoestrogenic properties (ERbeta-selective) may interact with hormone-dependent tumor biology [17][24]
• Concurrent use of dopaminergic medications (Parkinson's disease treatments): Theoretical additive or antagonistic effects on dopamine pathways [18][24]

Case reports of clinical significance:

• A woman with a prolactin-secreting microadenoma had her diagnosis masked by concurrent vitex use, as the prolactin-suppressive effect normalized serum prolactin levels without addressing the underlying tumor [7]
• Allergic dermatitis after single dose reported in at least one participant [7]

CYP450 interactions (in vitro): VAC inhibits CYP2C19 (IC50 0.22 ug/mL) and CYP3A4 (IC50 0.3 ug/mL) at potentially clinically relevant concentrations [18]. Drugs metabolized by these enzymes (e.g., omeprazole, clopidogrel for CYP2C19; simvastatin, certain immunosuppressants for CYP3A4) may have altered pharmacokinetics. Clinical relevance has not been established in human studies.

Knowing the possible side effects is the first step. Catching them early in your own experience is what keeps a supplement routine safe. Doserly lets you log any symptoms as they arise, tagging them with severity, timing relative to your dose, and whether they resolve on their own or persist.

The app's interaction checker cross-references everything in your stack, supplements and medications alike, flagging known interactions before they become a problem. It also monitors your total intake against established upper limits, alerting you if your combined sources of a nutrient are approaching thresholds where risk increases. Think of it as a safety net that works quietly in the background while you focus on the benefits.

Dosing & Usage Protocols

The Basics

Dosing chasteberry is somewhat more complex than many supplements because the dose depends heavily on which form and extract you are using. A standardized 10:1 concentrated extract requires only 4 mg per day, while a dried berry powder may need 150-250 mg per day. These are not interchangeable numbers; they reflect different concentrations of the same active compounds [7][9].

The most commonly studied and recommended dose ranges, based on clinical trial data, are:

• Standardized extract (BNO 1095): 4 mg once daily [9]
• Standardized extract (Ze 110 or Ze 440): 20 mg once daily [3][10]
• Dried fruit powder: 150-250 mg once daily [7]
• Liquid tincture: 40 drops once daily (approximately 4.5 mg of extract) [4]

Most clinical trials dosed chasteberry once daily in the morning, taken consistently throughout the entire menstrual cycle rather than only during specific phases [3][9][10]. Some practitioners and users take it only during the luteal phase (from ovulation to period onset), and anecdotal reports suggest comparable efficacy with this approach, though clinical trial data supporting this protocol is limited.

The clinical trials showing the strongest results ran for a minimum of three menstrual cycles (approximately three months). Some herbal medicine practitioners recommend continuing for six months before making a final assessment, and suggest taking periodic breaks [3][10]. Effects on breast tenderness may appear within the first cycle, while mood and cycle regulation typically require two to three cycles to become apparent.

The Science

Evidence-based dosing protocols from clinical trials:

Dose-response considerations: In healthy males, a biphasic prolactin response has been demonstrated: 120 mg/day of BP1095E1 extract increased prolactin (24-hour AUC), while 480 mg/day decreased it [19]. This suggests that dose optimization is important, and "more is not necessarily better." Whether this biphasic relationship extends to females in the context of PMS treatment is not established.

Duration: The minimum clinical trial duration showing robust effects is 3 menstrual cycles. The European Medicines Agency recommends use for up to 3 months, with reassessment if symptoms persist [8]. Some herbalists recommend 6-month courses followed by reassessment periods.

Cycling and discontinuation: No clinical trials have formally evaluated cycling protocols. Community reports suggest that symptom rebound may occur after discontinuation, indicating that VAC manages rather than corrects the underlying hormonal pattern. Gradual dose reduction rather than abrupt cessation may be advisable, though this has not been formally studied.

Getting the dose right matters more than most people realize. Too little may be ineffective, too much wastes money or introduces risk, and inconsistency undermines both. Doserly tracks every dose you take, across every form, giving you a clear record of what you're actually consuming versus what you planned.

The app helps you compare RDA recommendations against therapeutic ranges discussed in the research, so you can see exactly where your intake falls. If you switch forms, say from a standard capsule to a liposomal liquid, Doserly adjusts your tracking to account for different bioavailabilities. Pair that with smart reminders that keep your timing consistent, and the precision that makes a real difference in outcomes becomes effortless.

What to Expect (Timeline)

Week 1-2: Most users report no immediate changes. Some women notice a subtle shift in breast tenderness or slight mood improvement within the first 1-2 weeks. A minority may experience mild headaches or nausea as initial adjustment effects that typically resolve within the first week.

Week 3-4 (First cycle): Breast tenderness is often the first symptom to noticeably improve by the end of the first menstrual cycle. Some women report reduced bloating and slightly improved mood during their premenstrual phase. The first cycle may still include PMS symptoms, though they may feel somewhat dampened.

Month 2 (Second cycle): More consistent improvements in mood, irritability, and physical PMS symptoms become apparent for responders. Menstrual cycle regularity may begin to shift. Breast pain improvements typically consolidate. This is also the point where non-responders may begin to notice the lack of effect.

Month 3 (Third cycle): Clinical trials generally measure outcomes at this point. Full therapeutic effect is typically reached. In the Schellenberg (2001) trial, 52% of women experienced greater than 50% symptom reduction by this time [3]. Cycle regularity improvements, if occurring, are usually observable. Benefits to luteal phase length may be measurable via basal body temperature tracking.

Month 3-6: Some practitioners recommend continuing for up to six months for full hormonal rebalancing. Individual gains may continue to accrue. Periodic reassessment of symptom improvement is advisable.

After discontinuation: Community reports and limited clinical data suggest that benefits may not persist indefinitely after stopping. Some women report symptom return within one to two cycles after cessation, while others maintain improvements. The 20mg Ze 110 trial reported that symptom reduction decreased from 42-47% during treatment to 20-22% three months after stopping, indicating partial but not complete persistence of benefit [10].

Interactions & Compatibility

Synergistic

• Magnesium: Frequently combined in PMS management. Magnesium addresses muscle relaxation, sleep, and stress tolerance via separate pathways (NMDA receptor modulation, electrolyte balance). One trial found VAC superior to magnesium oxide for PMS, suggesting complementary rather than redundant mechanisms.
• Vitamin B6: Traditional combination for PMS. B6 supports serotonin and GABA synthesis. One trial found comparable efficacy between VAC and B6, suggesting possible additive benefit when combined.
• St. John's Wort: Both have dopaminergic activity. A 16-week double-blind trial of the combination in menopausal women with PMS-like symptoms showed some benefit for cravings and depression, though the combination was not more effective than either alone for all symptoms [25].
• Omega-3 Fatty Acids: Community protocols frequently include omega-3s alongside vitex for PMS management. No direct interaction data, but complementary anti-inflammatory mechanisms.
• B-Complex: Commonly stacked for hormonal health support. No interaction concerns identified.

Caution / Avoid

• Hormonal medications (oral contraceptives, HRT): Preclinical studies suggest VAC may decrease effectiveness of hormonal therapies through competitive binding at estrogen receptors and modulation of the HPG axis [17][18][24]. Clinical significance undetermined but theoretical risk warrants caution.
• Dopamine antagonist medications (antipsychotics: chlorpromazine, haloperidol, risperidone): VAC's dopaminergic activity may pharmacologically oppose D2 receptor blockade, potentially interfering with antipsychotic efficacy or enhancing side effects [18][24].
• Dopamine agonist medications (Parkinson's drugs: levodopa, bromocriptine, pramipexole): Additive dopaminergic effects could alter drug efficacy or side effect profile [18][24].
• CYP2C19 substrate drugs (omeprazole, clopidogrel, certain antidepressants): In vitro CYP2C19 inhibition (IC50 0.22 ug/mL) raises theoretical interaction risk [18].
• CYP3A4 substrate drugs (simvastatin, cyclosporine, certain HIV protease inhibitors): In vitro CYP3A4 inhibition (IC50 0.3 ug/mL) raises theoretical interaction risk [18].
• Maca: Both influence hormonal axes; combining without professional guidance may produce unpredictable hormonal effects.

How to Take / Administration Guide

• Recommended forms: Standardized ethanolic extracts (BNO 1095 or Ze 110/Ze 440) are the best-studied and most reliably dosed forms. These concentrate the lipophilic active compounds that drive the dopaminergic mechanism. Whole dried berry capsules are an alternative but require higher doses (150-250 mg) and are less standardized.
• Timing considerations: Most clinical trials and traditional use suggest taking chasteberry once daily in the morning. Consistent daily timing appears more important than relationship to meals. Some practitioners recommend taking it on an empty stomach for potentially faster absorption, though this is not clinically validated.
• Continuous vs. luteal-only dosing: Clinical trials predominantly used continuous daily dosing throughout the cycle. Some practitioners and users take vitex only during the luteal phase (ovulation to period onset). Both approaches have anecdotal support, but continuous dosing has stronger clinical trial backing.
• Avoid during pregnancy: Discontinue chasteberry immediately if pregnancy occurs or is suspected. Safety during pregnancy has not been established [24][27].
• Minimum trial period: Allow at least three full menstrual cycles (approximately three months) before evaluating efficacy. Some improvements (especially breast tenderness) may appear within the first cycle, but full mood and cycle regulation benefits typically require 2-3 cycles.
• Cycling guidance: The EMA recommends use for up to 3 months with reassessment [8]. Some herbalists suggest 6-month courses followed by a break of 1-2 months. If symptoms return after stopping, consult with a healthcare provider about long-term management strategies.

Choosing a Quality Product

• Third-party certifications: Look for products carrying USP Verified, NSF International, or GMP certification. These ensure that the product contains what the label claims and is free from common contaminants.
• Extract standardization: The best-studied extracts are standardized to specific active compound content. BNO 1095 is standardized for total diterpenoid content; Ze 110 is standardized for casticin (0.5-1.2% dry weight). Products listing a specific drug:extract ratio (e.g., 10:1 or 6-12:1) with identified extraction solvent (ethanol-based) are preferable.
• Active vs. cheap forms: Ethanolic extracts concentrate the dopaminergic diterpenoids that drive the primary mechanism of action. Water extracts or teas from chasteberry may have minimal therapeutic value, as the active compounds are lipophilic and poorly extracted by water [7].
• Red flags: Products making specific disease treatment claims (e.g., "cures infertility"), extremely high doses without clinical justification, proprietary blends that hide the actual vitex content, and products combining vitex with many other herbs without clear rationale.
• Supplement-specific quality markers: Casticin content (the primary quality marker for Ze 110 extracts), identification of the plant part used (fruit/berry is the studied part, not leaves or stems), and specification of extraction ratio.

Storage & Handling

Store chasteberry supplements in a cool, dry place away from direct sunlight and moisture. Most capsule and tablet forms are stable at room temperature (59-77 degrees F / 15-25 degrees C). Liquid tinctures should be stored in amber glass bottles and kept tightly sealed between uses to prevent oxidation and evaporation of the alcohol solvent. Whole dried berries should be stored in airtight containers and used within the manufacturer's expiration date. There are no reports of significant stability concerns beyond standard supplement handling practices.

Lifestyle & Supporting Factors

• Dietary context: Chasteberry is not a nutrient found in food, so dietary sources are not applicable. However, overall dietary quality influences hormonal health. Diets high in processed foods, sugar, and alcohol may exacerbate PMS symptoms independently of supplementation. Some practitioners recommend reducing caffeine and alcohol intake, particularly in the luteal phase, as complementary measures to vitex supplementation.
• Exercise: Regular moderate exercise has independent evidence for reducing PMS symptoms. Some users report that modifying exercise intensity during the luteal phase (reducing high-intensity training and substituting gentler activities like yoga or walking) complements vitex's effects.
• Stress management: Stress increases cortisol, which can disrupt the hypothalamic-pituitary-gonadal axis that vitex targets. Stress reduction practices may enhance vitex's effectiveness by reducing a competing source of hormonal disruption.
• Cycle tracking: Tracking menstrual cycle length, symptom timing, and symptom severity provides objective data to assess whether vitex is producing measurable improvements. Basal body temperature tracking can reveal changes in luteal phase length.
• Signs that may indicate a need for vitex: Short menstrual cycles (less than 24 days), breast tenderness before periods, PMS symptoms that begin more than a week before menstruation, irregular periods after discontinuing hormonal contraception.
• Who should avoid or use caution: Women with PCOS (particularly those with already-elevated LH), women with hormone-sensitive cancers, pregnant or breastfeeding women, and individuals taking dopaminergic medications or hormonal therapies.

Regulatory Status & Standards

United States (FDA): Chasteberry is classified as a dietary supplement under DSHEA. No FDA-approved health claims. No GRAS designation specifically for therapeutic use. Available over the counter without prescription.

Canada (Health Canada): Available as a Natural Health Product (NHP). Licensed NHP monograph exists for chasteberry for relief of symptoms of PMS.

European Union (EFSA/EMA): The European Medicines Agency (EMA) has issued a well-established use monograph for Vitex agnus-castus dry extract for PMS symptom relief [8]. In Germany, chasteberry is one of the most frequently prescribed herbal medicines for gynecological conditions. The Committee on Herbal Medicinal Products (HMPC) recognizes its traditional use.

Australia (TGA): Listed as a complementary medicine ingredient.

Athlete & Sports Regulatory Status: Vitex agnus-castus is not included on the WADA Prohibited List and is not known to be banned by any major national anti-doping agency (USADA, UKAD, Sport Integrity Canada, Sport Integrity Australia). It is not listed as a banned substance by the NCAA, NFL, NBA, MLB, NHL, or MLS. However, supplement contamination remains a general risk for athletes. Products carrying Informed Sport or NSF Certified for Sport certification provide the highest assurance against contamination with prohibited substances. Athletes can verify the status of specific products through GlobalDRO.com.

Regulatory status and prohibited substance classifications change frequently. Athletes should always verify the current status of any supplement with their sport's governing body, their national anti-doping agency, and a qualified sports medicine professional before use. Third-party certification (Informed Sport, NSF Certified for Sport) reduces but does not eliminate the risk of contamination with prohibited substances.

Frequently Asked Questions

How long does it take for vitex to work?
Based on available clinical data, most studies show measurable improvements after three menstrual cycles (approximately three months) of consistent daily use. Some women report noticing reduced breast tenderness within the first cycle, while mood and cycle regulation benefits typically take longer to emerge. Herbal medicine practitioners often recommend allowing six months for a thorough assessment [3][10].

Can I take vitex while on birth control?
Preclinical studies suggest that vitex may theoretically interfere with hormonal contraceptives by affecting the same hormonal pathways, though clinical evidence of actual interference is limited [18][24]. One small study noted that 16 participants concurrently used contraceptives without apparent problems [7]. However, given the theoretical risk, consulting with a healthcare provider before combining vitex with hormonal birth control is advisable.

Is vitex safe for PCOS?
Vitex may not be appropriate for all women with PCOS. Because it can increase luteinizing hormone (LH) levels, and many PCOS patients already have elevated LH relative to FSH, vitex could potentially worsen the hormonal imbalance driving PCOS symptoms [7]. Some community reports describe increased acne, bloating, and hair loss in PCOS users. A healthcare provider familiar with the individual's hormonal profile should guide this decision.

Should I take vitex every day or only during the luteal phase?
Clinical trials predominantly used continuous daily dosing throughout the menstrual cycle [3][9][10]. Some users and practitioners recommend luteal-phase-only dosing (from ovulation to period onset), and anecdotal reports suggest comparable effectiveness. However, the stronger evidence base supports daily continuous use.

Can vitex help with fertility?
One well-designed clinical trial showed that vitex normalized luteal phase length and progesterone production in women with luteal phase defects caused by mild prolactin elevation, and two participants became pregnant during the study [5]. However, evidence is limited to this single trial. Vitex should be discontinued if pregnancy occurs, as safety during pregnancy has not been established.

What happens when I stop taking vitex?
Clinical data and community reports suggest that benefits may diminish after discontinuation. One trial noted symptom reduction decreased from 42-47% during treatment to 20-22% three months after cessation [10]. Some users report symptom rebound within 1-2 cycles of stopping. This suggests vitex manages hormonal patterns rather than permanently correcting them.

Can men take vitex?
Most research and traditional use focus on women. In healthy males, vitex showed dose-dependent effects on prolactin (low doses increased it, high doses decreased it) and induced melatonin secretion, but did not affect testosterone at doses up to 480 mg/day over 20 days [7][19]. The anti-androgenic effects observed in animal studies at very high doses (equivalent to approximately 1.8-4 g of hydroalcoholic extract for a 150 lb male) are far above typical supplementation ranges.

Does vitex affect estrogen levels?
Despite being classified as containing phytoestrogens, vitex binds selectively to estrogen receptor beta (ERbeta) rather than estrogen receptor alpha (ERalpha). Since ERalpha drives most classic estrogenic effects in breast and uterine tissue, vitex's net effect may actually be anti-estrogenic in practice [16][17]. Animal studies showed estrogen increases at very high doses (600-1200 mg/kg), but these doses are far above human supplementation ranges.

Are there any serious side effects?
Serious side effects are rare in the available literature. The most concerning report involves a case where vitex masked a prolactin-secreting pituitary tumor by normalizing prolactin levels without addressing the underlying condition [7]. Allergic skin reactions have been reported in isolated cases. The European Medicines Agency assessment references potential liver concerns with prolonged use (6+ months), but this is poorly documented [8].

What brand or form should I choose?
Based on clinical trial evidence, standardized ethanolic extracts with specified drug:extract ratios (BNO 1095 at 10:1 or Ze 110 at 6-12:1) have the strongest evidence base. Look for products specifying casticin content or diterpenoid standardization. Third-party testing certifications (USP, NSF) provide additional quality assurance.

Myth vs. Fact

Myth: Vitex directly increases progesterone levels by acting like a hormone.
Fact: Vitex does not contain progesterone or act as a direct progesterone source. Instead, it acts upstream by reducing prolactin (via dopamine D2 receptor activation), which removes the inhibitory effect of excess prolactin on the corpus luteum. The resulting improvement in corpus luteum function allows the body to produce adequate progesterone on its own [5][6][13].

Myth: Chasteberry is a phytoestrogen that will increase estrogen levels.
Fact: While chasteberry does contain compounds that bind to estrogen receptors, this binding is selective for the beta subunit (ERbeta), not the alpha subunit (ERalpha) responsible for classic estrogenic effects. The net effect may actually be anti-estrogenic, as ERbeta activation can oppose ERalpha-mediated proliferative effects [16][17]. Animal studies showing estrogen increases used doses far exceeding human supplementation ranges.

Myth: You should feel the effects of vitex within the first few days.
Fact: While some users report subtle improvements early on, clinical trials consistently show that the minimum reliable assessment period is three menstrual cycles (approximately three months). Breast tenderness may improve first, but mood and cycle regulation benefits typically require 2-3 cycles to manifest [3][10]. Expecting immediate results may lead to premature discontinuation.

Myth: Vitex is safe for all women with hormonal issues.
Fact: Vitex may worsen symptoms in women with PCOS, particularly those with already-elevated LH levels, by further increasing LH and potentially amplifying androgen-driven symptoms [7]. It is also not recommended for women with hormone-sensitive cancers, during pregnancy or breastfeeding, or for those taking dopaminergic medications [24][27].

Myth: Higher doses of vitex produce better results.
Fact: In healthy males, a biphasic prolactin response was observed: low doses (120 mg/day) actually increased prolactin, while higher doses (480 mg/day) decreased it [19]. Clinical trial data shows that very small doses of standardized extracts (as low as 4 mg of BNO 1095) are effective for PMS. The relationship between dose and benefit is not linear, and exceeding studied doses may not improve outcomes.

Myth: Vitex tea is just as effective as capsule supplements.
Fact: The active compounds in chasteberry (clerodane diterpenoids, casticin) are lipophilic (fat-soluble) and concentrate in ethanolic/hexane extracts. Water extracts show no significant dopaminergic activity in laboratory testing [7]. While chasteberry tea has traditional use, the evidence for therapeutic benefit comes specifically from ethanolic extracts, and water-based preparations may deliver insufficient quantities of the active compounds.

Myth: Once vitex corrects your hormones, you can stop taking it and the benefits will last.
Fact: Clinical data and community reports suggest that benefits typically diminish after discontinuation. One trial found symptom reduction dropped from 42-47% during treatment to 20-22% three months after stopping [10]. Multiple community users report symptom return within 1-2 cycles of cessation. Vitex appears to manage hormonal patterns rather than permanently reset them.

Sources & References

Systematic Reviews & Meta-Analyses

[1] Kamal N, Mio Asni NS, Rozlan INA, et al. Traditional medicinal uses, phytochemistry, biological properties, and health applications of Vitex sp. Plants. 2022;11(15):1944.

[2] Wuttke W, Jarry H, Christoffel V, et al. Chaste tree (Vitex agnus-castus): pharmacology and clinical indications. Phytomedicine. 2003 May;10(4):348-357.

[3] Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective, randomised, placebo controlled study. BMJ. 2001 Jan 20;322(7279):134-137.

[4] Verkaik S, Kamperman AM, van Westrhenen R, Schulte PFJ. The treatment of premenstrual syndrome with preparations of Vitex agnus castus: a systematic review and meta-analysis. Am J Obstet Gynecol. 2017 Aug;217(2):150-166.

[5] Milewicz A, Gejdel E, Sworen H, et al. Vitex agnus castus extract in the treatment of luteal phase defects due to latent hyperprolactinemia. Results of a randomized placebo-controlled double-blind study. Arzneimittelforschung. 1993;43(7):752-756.

[6] Jarry H, Leonhardt S, Gorkow C, Wuttke W. In vitro prolactin but not LH and FSH release is inhibited by compounds in extracts of Agnus castus: direct evidence for a dopaminergic principle by the dopamine receptor assay. Exp Clin Endocrinol. 1994;102(6):448-454.

[7] Multiple primary sources compiled in knowledge base review of Vitex agnus-castus phytochemistry and pharmacology. Individual citations traced inline throughout the guide.

[8] European Medicines Agency (EMA). Committee on Herbal Medicinal Products (HMPC). Community herbal monograph on Vitex agnus-castus L., fructus.

[9] He Z, Chen R, Zhou Y, et al. Treatment for premenstrual syndrome with Vitex agnus castus: a prospective, randomized, multi-center placebo controlled study in China. Maturitas. 2009 May 20;63(1):99-103.

[10] Berger D, Schaffner W, Schrader E, et al. Efficacy of Vitex agnus castus L. extract Ze 440 in patients with pre-menstrual syndrome (PMS). Arch Gynecol Obstet. 2000;264(3):150-153.

[11] Lucks B. Vitex agnus-castus essential oil and menopausal balance: a research update. Complement Ther Nurs Midwifery. 2003 Aug;9(3):157-160.

[12] Sliutz G, Speiser P, Schultz AM, Spona J, Zeillinger R. Agnus castus extracts inhibit prolactin secretion of rat pituitary cells. Horm Metab Res. 1993;25(5):253-255.

[13] Wuttke W, et al. The premenstrual syndrome, premenstrual mastodynia, fibrocystic mastopathy and infertility have often common roots: effects of extracts of chasteberry (Vitex agnus castus) as a solution. Clin Phytosci. 2017;3:6.

[14] Webster DE, He Y, Chen SN, et al. Opioidergic mechanisms underlying the actions of Vitex agnus-castus L. Biochem Pharmacol. 2011 Jan 1;81(1):170-177.

[15] Webster DE, Lu J, Chen SN, et al. Activation of the mu-opiate receptor by Vitex agnus-castus methanol extracts: implication for its use in PMS. J Ethnopharmacol. 2006;106(2):216-221.

[16] Jarry H, Spengler B, Porzel A, et al. Evidence for estrogen receptor beta-selective activity of Vitex agnus-castus and isolated flavones. Planta Med. 2003 Oct;69(10):945-947.

[17] Liu J, Burdette JE, Sun Y, et al. Isolation of linoleic acid as an estrogenic compound from the fruits of Vitex agnus-castus L. (chaste-berry). Phytomedicine. 2004 Jan;11(1):18-23.

[18] Ho SH, Singh M, Holloway AC, et al. The effects of commercial preparations of herbal supplements commonly used by women on the biotransformation of fluorogenic substrates by human cytochromes P450. Phytother Res. 2011 Jul;25(7):983-989.

[19] Merz PG, Gorkow C, Schroder A, et al. The effects of a special Agnus castus extract (BP 1095E1) on prolactin secretion in healthy male subjects. Exp Clin Endocrinol Diabetes. 1996;104(6):447-453.

[20] Csupor D, Lantos T, Hegyi P, et al. Vitex agnus-castus in premenstrual syndrome: a meta-analysis of double-blind randomised controlled trials. Complement Ther Med. 2019;47:102190.

[21] Atmaca M, Kumru S, Tezcan E. Fluoxetine versus Vitex agnus castus extract in the treatment of premenstrual dysphoric disorder. Hum Psychopharmacol. 2003;18(3):191-195.

[22] Van Die MD, Burger HG, Teede HJ, Bone KM. Vitex agnus-castus extracts for female reproductive disorders: a systematic review of clinical trials. Planta Med. 2013;79(7):562-575.

[23] Ooi SL, Watts S, McClean R, et al. Vitex agnus-castus for the treatment of cyclic mastalgia: a systematic review and meta-analysis. J Womens Health. 2020;29(2):262-278.

[24] Dugoua JJ, Seely D, Perri D, et al. Safety and efficacy of chastetree (Vitex agnus-castus) during pregnancy and lactation. Can J Clin Pharmacol. 2008 Winter;15(1):e74-e79.

[25] Van Die MD, Burger HG, Bone KM, et al. Hypericum perforatum with Vitex agnus-castus in menopausal symptoms: a randomized, controlled trial. Menopause. 2009 Jan-Feb;16(1):156-163.

[26] Holler M, Steindl H, Abramov-Sommariva D, et al. Use of Vitex agnus-castus in patients with menstrual cycle disorders: a single-center retrospective longitudinal cohort study. Arch Gynecol Obstet. 2024;309(5):2089-2098.

[27] Daniele C, Thompson Coon J, Pittler MH, et al. Vitex agnus castus: a systematic review of adverse events. Drug Saf. 2005;28(4):319-332.

Government & Institutional Sources

[8] European Medicines Agency (EMA) HMPC Monograph on Vitex agnus-castus

Clinical Trials

[3] Schellenberg 2001 (BMJ) — Landmark RCT, Ze 440, PMS
[5] Milewicz 1993 — RCT, Luteal phase defects
[9] He 2009 — RCT, BNO 1095, Chinese PMS cohort
[10] Berger 2000 — RCT, Ze 440, PMS

Related Supplement Guides

Same Category (Herbal / Women's Health)

• Black Cohosh
• Dong Quai
• Red Clover
• Maca
• Shatavari
• Evening Primrose Oil

Common Stacks / Pairings

• Magnesium — PMS symptom management
• Vitamin B6 — Hormonal support
• St. John's Wort — Mood and hormonal support
• Fish Oil (EPA/DHA) — Anti-inflammatory, PMS support
• B-Complex — Overall hormonal health

Related Health Goal

• Inositol — Hormonal balance, PCOS
• DIM (Diindolylmethane) — Estrogen metabolism
• Calcium-D-Glucarate — Estrogen detoxification
• Iron — Menstrual health, anemia risk with heavy periods